An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2018
At a glance
- Drugs CC 223 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms TORCH
- Sponsors Antengene Corporation
- 07 Aug 2018 Status changed from not yet recruiting to recruiting.
- 20 Jul 2018 Status changed from planning to recruiting, according to a STA Pharmaceutical media release.
- 19 Jun 2018 New trial record